Stay updated on Pemigatinib Dose-Escalation Clinical Trial

Sign up to get notified when there's something new on the Pemigatinib Dose-Escalation Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pemigatinib Dose-Escalation Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.2%
    Check dated 2025-04-30T13:42:38.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Difference
    0.3%
    Check dated 2025-04-23T08:11:41.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The page has undergone significant updates, including the addition of new drugs such as Docetaxel, Trastuzumab, Retifanlimab, and Cisplatin, while removing detailed descriptions of a study related to pemigatinib and other investigational drugs.
    Difference
    6%
    Check dated 2025-04-16T01:15:51.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.2%
    Check dated 2025-04-08T19:44:01.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The page has been updated to include information on Multiple Myeloma while removing references to Bile Duct Cancer, indicating a shift in focus towards a different type of cancer. Additionally, the revision number has been updated from v2.14.2 to v2.14.3.
    Difference
    0.2%
    Check dated 2025-04-01T13:39:45.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Difference
    0.2%
    Check dated 2025-03-25T04:48:42.000Z thumbnail image

Stay in the know with updates to Pemigatinib Dose-Escalation Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pemigatinib Dose-Escalation Clinical Trial page.